Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Glob Oncol ; 5: 1-19, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31774711

RESUMO

PURPOSE: Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL. METHODS: This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4). RESULTS: Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. CONCLUSION: The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.


Assuntos
Leucemia Linfocítica Crônica de Células B/epidemiologia , Linfoma não Hodgkin/epidemiologia , Mieloma Múltiplo/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Humanos , América Latina/epidemiologia , Pessoa de Meia-Idade , Sistema de Registros , Adulto Jovem
2.
Med. UIS ; 30(2): 55-62, mayo-ago. 2017. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-894206

RESUMO

RESUMEN Introducción: las metaloproteinasas son enzimas fundamentales para el mantenimiento estructural de la matriz extracelular, así como para su degradación en situaciones donde se requiere un proceso de reparación tisular. Objetivo: realizar una revisión de los aspectos más actuales de las metaloproteinasas y su papel en la cicatrización. Metodología de búsqueda: se realizó una revisión de 95 artículos, durante el período comprendido entre el 18 de julio de 2015 y 20 de septiembre de 2016 se utilizó las bases de datos Medline, Scopus, Scielo y Science Direct. Resultados: existen seis subfamilias de metaloproteinasas: colagenasas, estromalisinas, elastasas, gelatinasas, matrilisinas y las metaloproteinasas asociadas a la membrana plasmática. Las células endoteliales vasculares las secretan en donde hay daño epitelial y se requiere de un proceso de cicatrización. Conclusiones: las metaloproteinasas son endopeptidasas dependientes de zinc fundamentales para el mantenimiento y degradación de la matriz extracelular. Cuando el mecanismo de regulación falla y las metaloproteinasas tienen una sobreexpresión, ocurren procesos de cicatrización deficientes, condicionando la aparición de heridas crónicas, cicatrices hipertróficas o queloides, pterigión, fibrosis pulmonar y hepática, entre otras condiciones. MÉD.UIS. 2017;30(2):55-62.


ABSTRACT Introduction: Matrix metalloproteinases are essential for structural maintenance of extracellular matrix enzymes, as well as degradation in situations where tissue repair process is warranted. Objective: To review the most current aspects of matrix metalloproteinases and their role in the healing process. Research Methodology: A review of about 95 papers was conducted during the period from July 18, 2015 to September 20, 2016; PubMed, Scopus, Scielo and Science Direct were used. Results: There are six subfamilies of metalloproteinases: collagenases, stromalysins, elastases, gelatinases, matrilysins and metalloproteinases associated with the plasma membrane. Vascular endothelial cells secrete them where there is epithelial damage and a healing process is required. Conclusions: Metalloproteinases are zinc dependent endopeptidases that are essential for the maintenance and degradation of the extracellular matrix. When the adjustment mechanism fails and matrix metalloproteinases are overexpressed, poor healing processes occur, causing problems such as liver chronic wounds, keloids or hypertrophic scars, pterygium, pulmonary and liver fibrosis, among other clinical conditions. MÉD.UIS. 2017;30(2):55-62.


Assuntos
Humanos , Masculino , Feminino , Metaloproteinases da Matriz , Matriz Extracelular , Cicatrização , Pterígio , Endotélio Vascular , Metaloproteinase 7 da Matriz , Metaloproteinases da Matriz Associadas à Membrana , Queloide
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA